BRAF, a key molecule in the EGFR/RAS downstream signaling pathway, is mutated in approximately 1.5%–5.5% NSCLC cases, with the predominant genotype being BRAF V600E (Jordan et al., 2017; Lin et al., 2019). Here, BRAF is linked to non-small cell lung carcinoma.